Plasma biomarkers of depressive symptoms in older adults

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Arnold, S E ^a   Xie, S X ^a   Leung, Y Y ^a   Wang, L S ^a   Kling, M A ^a   Han, X ^a   Kim, E J ^a   Wolk, D A ^a   Bennett, D A ^b   Chen Plotkin, A ^a   Grossman, M ^a   Hu, W ^c   Lee, V M Y ^a   MacKin, R Scott ^d   Trojanowski, J Q ^a   Wilson, R S ^b   Shaw, L M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease neuroimaging initiative; biochemical biomarker; geriatric depression; mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; HGF PROTEIN, HUMAN; INSULIN; PEPTIDE FRAGMENT; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SCATTER FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL INTELLIGENCE; BLOOD; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; REFERENCE VALUE; STATISTICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARTIFICIAL INTELLIGENCE; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REFERENCE VALUES; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863018225     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.63     Document Type: Article

References (78)

1. Meeks TW, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in "a minor" can "b major": a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. J Affect Disord 2010; 129: 126-142.
2. Thielke SM, Diehr P, Unutzer J. Prevalence, incidence, and persistence of major depressive symptoms in the Cardiovascular Health Study. Aging Ment Health 2010; 14: 168-176.
3. Dozeman E, van Marwijk HW, van Schaik DJ, Stek ML, van der Horst HE, Beekman AT et al. High incidence of clinically relevant depressive symptoms in vulnerable persons of 75 years or older living in the community. Aging Ment Health 2010; 14: 828-833.
4. Lyness JM, Heo M, Datto CJ, Ten Have TR, Katz IR, Drayer R et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med 2006; 144: 496-504. (Pubitemid 46780672)
5. Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 2011; 23: 177-193.
6. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009; 8: 1128-1139.
7. Fang J, Cheng Q. Etiological mechanisms of post-stroke depression: a review. Neurol Res 2009; 31: 904-909.
8. Flicker L. Cardiovascular risk factors, cerebrovascular disease burden, and healthy brain aging. Clin Geriatr Med 2010; 26: 17-27.
9. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord 2008; 106: 249-255.
10. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003; 54: 566-572. (Pubitemid 37289443)
11. Forti P, Rietti E, Pisacane N, Olivelli V, Mariani E, Chiappelli M et al. Blood inflammatory proteins and risk of incident depression in the elderly. Dement Geriatr Cogn Disord 2010; 29: 11-20.
12. Bremmer MA, Deeg DJ, Beekman AT, Penninx BW, Lips P, Hoogendijk WJ. Major depression in late life is associated with both hypo- and hypercortisolemia. Biol Psychiatry 2007; 62: 479-486. (Pubitemid 47284034)
13. Amato L, Paolisso G, Cacciatore F, Ferrara N, Canonico S, Rengo F et al. Non-insulindependent diabetes mellitus is associated with a greater prevalence of depression in the elderly. The Osservatorio Geriatrico of Campania Region Group. Diabetes Metab 1996; 22: 314-318. (Pubitemid 26323438)
14. Lee KS, Chung JH, Lee KH, Shin MJ, Oh BH, Lee SH et al. Simultaneous measurement of 23 plasma cytokines in late-life depression. Neurol Sci 2009; 30: 435-438.
15. Diniz BS, Teixeira AL, Talib LL, Mendonca VA, Gattaz WF, Forlenza OV. Serum brainderived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World J Biol Psychiatry 2010; 11: 550-555.
16. Shi Y, You J, Yuan Y, Zhang X, Li H, Hou G. Plasma BDNF and tPA are associated with late-onset geriatric depression. Psychiatry Clin Neurosci 2010; 64: 249-254.
17. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004; 29: 795-798. (Pubitemid 38402487)
18. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005; 15: 869-877, xi-xii.. (Pubitemid 43162384)
19. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010; 6: 239-246.
20. Weiner MW, Aisen PS, Jack Jr CR, Jagust WJ, Trojanowski JQ, Shaw L et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202-211, e207.
21. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201-209.
22. Shaw LM. PENN Biomarker Core of the Alzheimer's Disease Neuroimaging Initiative. Neurosignals 2008; 16: 19-23. (Pubitemid 350308317)
23. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49. (Pubitemid 13123113)
24. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 1999; 14: 858-865. (Pubitemid 29495547)
25. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005; 1: 55-66. (Pubitemid 43348857)
26. Friedman B, Heisel MJ, Delavan RL. Psychometric properties of the 15-item geriatric depression scale in functionally impaired, cognitively intact, community-dwelling elderly primary care patients. J Am Geriatr Soc 2005; 53: 1570-1576. (Pubitemid 41602449)
27. Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP et al. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Int J Geriatr Psychiatry 2009; 24: 556-562.
28. Burke WJ, Roccaforte WH, Wengel SP. The short form of the geriatric depression scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol 1991; 4: 173-178.
29. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414. (Pubitemid 23346995)
30. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010; 6: 230-238.
31. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362. (Pubitemid 350073592)
32. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
33. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-488. (Pubitemid 10073130)
34. Carroll BJ, Martin FI, Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. Br Med J 1968; 3: 285-287.
35. Belmaker R, Beckmann H, Goodwin F, Murphy D, Pollin W, Buchsbaum M et al. Relationships between platelet and plasma monoamine oxidase, plasma dopamine-betahydroxylase, and urinary 3-methoxy-4-hydroxy phenylglycol. Life Sci 1975; 16: 273-280.
36. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-148. (Pubitemid 34258493)
37. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 588-610.
38. Jung W, Castren E, Odenthal M, Vande Woude GF, Ishii T, Dienes HP et al. Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol 1994; 126: 485-494. (Pubitemid 24226264)
39. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003; 23: 622-631. (Pubitemid 36139561)
40. Nagayama T, Nagayama M, Kohara S, Kamiguchi H, Shibuya M, Katoh Y et al. Postischemic delayed expression of hepatocyte growth factor and c-Met in mouse brain following focal cerebral ischemia. Brain Res 2004; 999: 155-166. (Pubitemid 38167388)
41. Fenton H, Finch PW, Rubin JS, Rosenberg JM, Taylor WG, Kuo-Leblanc V et al. Hepatocyte growth factor (HGF/SF) in Alzheimer's disease. Brain Res 1998; 779: 262-270. (Pubitemid 28039960)
42. Akimoto M, Baba A, Ikeda-Matsuo Y, Yamada MK, Itamura R, Nishiyama N et al. Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus. Neuroscience 2004; 128: 155-162. (Pubitemid 39140688)
43. Date I, Takagi N, Takagi K, Kago T, Matsumoto K, Nakamura T et al. Hepatocyte growth factor improved learning and memory dysfunction of microsphere-embolized rats. J Neurosci Res 2004; 78: 442-453. (Pubitemid 39488268)
44. Takeuchi D, Sato N, Shimamura M, Kurinami H, Takeda S, Shinohara M et al. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Therapy 2008; 15: 561-571.
45. Isogawa K, Akiyoshi J, Kodama K, Matsushita H, Tsutsumi T, Funakoshi H et al. Anxiolytic effect of hepatocyte growth factor infused into rat brain. Neuropsychobiology 2005; 51: 34-38. (Pubitemid 40867988)
46. Wakatsuki M, Akiyoshi J, Ichioka S, Tanaka Y, Tsuru J, Matsushita H et al. Administration of antisense DNA for hepatocyte growth factor causes an depressive and anxiogenic response in rats. Neuropeptides 2007; 41: 477-483. (Pubitemid 350101820)
47. Russo AJ. Decreased serum hepatocyte growth factor (HGF) in individuals with depression correlates with severity of disease. Biomark Insights 2010; 5: 63-67.
48. Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009; 34: 353-357.
49. Kanehisa M, Ishitobi Y, Ando T, Okamoto S, Maruyama Y, Kohno K et al. Serum hepatocyte growth factor levels and the effects of antidepressants in panic disorder. Neuropeptides 2010; 44: 431-435.
50. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49: 1255-1260.
51. Pouwer F, Beekman AT, Nijpels G, Dekker JM, Snoek FJ, Kostense PJ et al. Rates and risks for co-morbid depression in patients with Type 2 diabetes mellitus: results from a community-based study. Diabetologia 2003; 46: 892-898. (Pubitemid 36961312)
52. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010; 170: 1884-1891.
53. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856-1861. (Pubitemid 46048182)
54. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-845.
55. Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schrager M et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 2007; 32: 151-159. (Pubitemid 46274017)
56. Lute BJ, Khoshbouei H, Saunders C, Sen N, Lin RZ, Javitch JA et al. PI3K signaling supports amphetamine-induced dopamine efflux. Biochem Biophys Res Commun 2008; 372: 656-661.
57. Robertson SD, Matthies HJ, Owens WA, Sathananthan V, Christianson NS, Kennedy JP et al. Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J Neurosci 2010; 30: 11305-11316.
58. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2004; 131: 1187-1194. (Pubitemid 38380471)
59. Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setala-Soikkeli E et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett 2010; 477: 105-108.
60. Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ et al. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 2009; 169: 113-117.
61. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 658-663. (Pubitemid 46476822)
62. Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm 2010; 117: 1119-1122.
63. Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielsen MG, Gennarelli M et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 146-149.
64. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
65. Rigau V, Morin M, Rousset MC, de Bock F, Lebrun A, Coubes P et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007; 130(Pt 7): 1942-1956. (Pubitemid 47343810)
66. Udo H, Yoshida Y, Kino T, Ohnuki K, Mizunoya W, Mukuda T et al. Enhanced adult neurogenesis and angiogenesis and altered affective behaviors in mice overexpressing vascular endothelial growth factor 120. J Neurosci 2008; 28: 14522-14536.
67. McCloskey DP, Croll SD, Scharfman HE. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J Neurosci 2005; 25: 8889-8897. (Pubitemid 41384456)
68. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004; 36: 827-835. (Pubitemid 39014099)
69. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 230-233.
70. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166.
71. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
72. Swardfager W, Lanctot K, Rothenburg L,Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010; 68: 930-941.
73. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology 2006; 27: 143-153. (Pubitemid 44651434)
74. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002; 59: 364-370. (Pubitemid 34857928)
75. Yaffe K, Vittinghoff E, Lindquist K, Barnes D, Covinsky KE, Neylan T et al. Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry 2010; 67: 608-613.
76. Crowe M, Andel R, Pedersen NL, Gatz M. Do work-related stress and reactivity to stress predict dementia more than 30 years later? Alzheimer Dis Assoc Disord 2007; 21: 205-209. (Pubitemid 47367972)
77. Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med 2007; 69: 47-53. (Pubitemid 46148364)
78. Milwain EJ, Nagy Z. Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology. Dement Geriatr Cogn Disord 2005; 19: 46-50. (Pubitemid 39664189)